Source comparison
MK-677 Oral Ghrelin Receptor Agonism Versus Injectable Secretagogues
The distinction between MK-677 and peptide-based growth hormone secretagogues like GHRP-6, GHRP-2, Ipamorelin, and Hexarelin comes down to structure, bioavailability, and receptor selectivity. Peptide secretagogues require subcutaneous or intravenous administr
This comparison does not assign a generated winner or score.
- The distinction between MK-677 and peptide-based growth hormone secretagogues like GHRP-6, GHRP-2, Ipamorelin, and Hexarelin comes down to structure, bioavailability, and receptor selectivity. Peptide secretagogues require subcutaneous or intravenous administration because they are degraded by gastric acid and intestinal peptidases. Oral bioavailability is negligible. MK-677, as a non-peptide small molecule, survives gastrointestinal transit and achieves approximately 60–70% oral bioavailability, making it the only secretagogue in this class that can be administered orally with reliable systemic exposure.
- Receptor selectivity also differs. While GHRP-6 and GHRP-2 activate GHS-R1a, they also exhibit off-target activity at acetylcholine receptors and cortisol pathways, producing side effects like transient increases in cortisol and prolactin. MK-677 demonstrates high selectivity for GHS-R1a with minimal cross-reactivity. Clinical studies have shown no significant elevation in cortisol or ACTH at standard research doses. A double-blind, placebo-controlled trial in healthy adults found that 25mg daily MK-677 increased IGF-1 by 60% with no statistically significant change in cortisol, thyroid-stimulating hormone, or prolactin levels.
- Duration of action is another differentiator. Peptide secretagogues like Ipamorelin and Hexarelin have half-lives measured in minutes to hours, requiring multiple daily injections to sustain GH elevation. MK-677 oral ghrelin receptor agonism produces effects lasting 24 hours from a single oral dose, simplifying dosing protocols in experimental models where frequent handling or injection stress could confound results. For researchers modeling chronic GH deficiency or age-related somatopause, this extended duration more closely approximates the continuous low-level ghrelin signaling seen in fasting states.
- One notable limitation: MK-677 does not synergize with GHRH the way some peptide secretagogues do. CJC-1295 Ipamorelin combinations leverage the additive effect of simultaneous GHRH (growth hormone-releasing hormone) and ghrelin receptor activation to produce supra-physiological GH pulses. MK-677 acts exclusively through the ghrelin pathway. It amplifies endogenous pulsatile secretion but does not create the exaggerated peaks seen with dual-agonist protocols. For studies requiring maximal acute GH release, injectable combinations may remain preferable. For studies requiring sustained, physiologically patterned GH elevation over weeks to months, MK-677 oral ghrelin receptor agonism offers cleaner pharmacokinetics and eliminates injection-site variables.